Clinical Trials Directory

Trials / Completed

CompletedNCT00483457

Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer Patients

Pilot Study of the Effects of Epidermal Growth Factor Receptor (EGFR) Inhibitors on the EGFR in Skin Lesions

Status
Completed
Phase
Study type
Observational
Enrollment
33 (actual)
Sponsor
Vanderbilt-Ingram Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying samples of tissue and blood in the laboratory from patients with cancer receiving epidermal growth factor receptor (EGFR) inhibitors may help doctors understand the effects of EGFR inhibitor therapy in the skin. PURPOSE: This laboratory study is looking at the effects of EGFR inhibitors in the skin of cancer patients.

Detailed description

OBJECTIVES: * Determine the effects of EGFR inhibitors on the EGFR pathway in the skin of cancer patients prior to and after receiving EGFR inhibitors (i.e., tyrosine kinase inhibitors and monoclonal antibodies). * Compare the effects of EGFR tyrosine kinase inhibitors vs monoclonal antibodies on the EGFR pathway in the skin of these patients. * Compare changes in the EGFR pathway with grade of rash in these patients. * Compare changes in EGFR pathway effectors in the skin with serum TGFα levels in these patients. OUTLINE: This is a pilot study. Patients undergo skin punch biopsies and blood sample collection at baseline, within 1 week of developing skin rash, and 6 weeks after beginning treatment. Samples are analyzed by immunohistochemistry and western blot for phosphorylated MAP kinase, AKT, and EGF levels and TGFα levels. Patients also complete diagrams to indicate locations of the rash once weekly during the first 6 weeks of treatment.

Conditions

Interventions

TypeNameDescription
DRUGenzyme inhibitor therapyenzyme inhibitor therapy
GENETICprotein expression analysisprotein expression analysis
OTHERimmunohistochemistry staining methodimmunohistochemistry staining method
OTHERlaboratory biomarker analysislaboratory biomarker analysis
PROCEDUREbiopsybiopsy

Timeline

Start date
2006-02-01
Primary completion
2008-11-01
Completion
2008-11-01
First posted
2007-06-07
Last updated
2012-09-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00483457. Inclusion in this directory is not an endorsement.